关于肢端肥大症并发症的诊断和治疗的共识。
A consensus on the diagnosis and treatment of acromegaly complications.
机构信息
Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Room 2015, Los Angeles, CA 90048, USA.
出版信息
Pituitary. 2013 Sep;16(3):294-302. doi: 10.1007/s11102-012-0420-x.
Abstract
In March 2011, the Acromegaly Consensus Group met to revise and update the guidelines on the diagnosis and treatment of acromegaly complications. The meeting was sponsored by the Pituitary Society and the European Neuroendocrinology Association and included experts skilled in the management of acromegaly. Complications considered included cardiovascular, endocrine and metabolic, sleep apnea, bone diseases, and mortality. Outcomes in selected, related clinical conditions were also considered, and included pregnancy, familial acromegaly and invasive macroadenomas. The need for a new disease staging model was considered, and design of such a tool was proposed.
摘要
2011 年 3 月，肢端肥大症共识小组召开会议，修订和更新肢端肥大症并发症的诊断和治疗指南。会议由垂体学会和欧洲神经内分泌协会主办，邀请了肢端肥大症管理方面的专家参加。所考虑的并发症包括心血管、内分泌和代谢、睡眠呼吸暂停、骨疾病和死亡率。还考虑了选定的相关临床情况的结果，包括妊娠、家族性肢端肥大症和侵袭性大腺瘤。会议认为有必要建立新的疾病分期模型，并提出了此类工具的设计方案。
相似文献
1
A consensus on the diagnosis and treatment of acromegaly complications.关于肢端肥大症并发症的诊断和治疗的共识。
Pituitary. 2013 Sep;16(3):294-302. doi: 10.1007/s11102-012-0420-x.
2
Sleep apnea and cardiovascular complications of the acromegaly. Response to the medical treatment.肢端肥大症的睡眠呼吸暂停和心血管并发症。对药物治疗的反应。
Minerva Endocrinol. 2019 Jun;44(2):159-168. doi: 10.23736/S0391-1977.18.02930-9. Epub 2018 Nov 26.
3
Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: Expert consensus.肢端肥大症的诊断及术后监测标准，及其合并症的筛查与管理：专家共识
Endocrinol Diabetes Nutr (Engl Ed). 2018 May;65(5):297-305. doi: 10.1016/j.endinu.2018.01.008. Epub 2018 Apr 10.
4
Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.肢端肥大症的并发症：心血管、呼吸及代谢共病
Pituitary. 2017 Feb;20(1):46-62. doi: 10.1007/s11102-017-0797-7.
5
Diagnosis and treatment of acromegaly and its complications: consensus guidelines.肢端肥大症及其并发症的诊断与治疗：共识指南
J Endocrinol Invest. 2005;28(11 Suppl International):43-7.
6
Diagnosis and treatment of acromegaly complications.肢端肥大症并发症的诊断与治疗
J Endocrinol Invest. 2003 Dec;26(12):1242-7. doi: 10.1007/BF03349164.
7
Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study.意大利肢端肥大症心血管并发症的认知与管理评估。COM.E.T.A.（肢端肥大症合并症评估与治疗）研究。
J Endocrinol Invest. 2008 Aug;31(8):731-8. doi: 10.1007/BF03346423.
8
Editorial: Health-Related Complications of Acromegaly.社论：肢端肥大症的健康相关并发症
Front Endocrinol (Lausanne). 2020 Jul 29;11:496. doi: 10.3389/fendo.2020.00496. eCollection 2020.
9
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update.肢端肥大症合并症的诊断与治疗共识：更新版。
J Clin Endocrinol Metab. 2020 Apr 1;105(4). doi: 10.1210/clinem/dgz096.
10
[Acromegaly with the sleep apnea syndrome].[肢端肥大症伴睡眠呼吸暂停综合征]
Acta Med Port. 1997 Dec;10(12):955-9.
引用本文的文献
1
Consensus on acromegaly therapeutic outcomes: an update.肢端肥大症治疗结果共识：最新进展
Nat Rev Endocrinol. 2025 Aug 13. doi: 10.1038/s41574-025-01148-2.
2
Anesthetic Considerations for the Transsphenoidal Resection of a Pituitary Tumor in an Acromegalic Patient: A Case Report.肢端肥大症患者经蝶窦垂体瘤切除术的麻醉考量：一例报告
Cureus. 2025 Apr 17;17(4):e82447. doi: 10.7759/cureus.82447. eCollection 2025 Apr.
3
Prevalence and risk factors of colon polyps and other colonic lesions in acromegaly: Insights from colonoscopy screening.肢端肥大症患者结肠息肉及其他结肠病变的患病率和危险因素：结肠镜筛查的见解
Pituitary. 2025 Apr 1;28(2):44. doi: 10.1007/s11102-025-01513-4.
4
Headache characteristics in acromegaly: Only a secondary disorder?肢端肥大症的头痛特征：仅是一种继发性病症？
Headache. 2025 May;65(5):826-834. doi: 10.1111/head.14927. Epub 2025 Mar 13.
5
Biochemical remission, diagnostic delays, and comorbidities of acromegaly in China: a large single-centre retrospective study.中国肢端肥大症的生化缓解、诊断延迟及合并症：一项大型单中心回顾性研究
Front Endocrinol (Lausanne). 2025 Feb 24;16:1526625. doi: 10.3389/fendo.2025.1526625. eCollection 2025.
6
IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly.标准剂量兰瑞肽治疗期间的胰岛素样生长因子-I水平可预测肢端肥大症高频治疗方案的生化疗效。
Pituitary. 2024 Dec 26;28(1):7. doi: 10.1007/s11102-024-01479-9.
7
Ends of the spectrum best practices for early detection and multidisciplinary management of acromegaly.肢端肥大症早期检测与多学科管理的最佳实践范围的两端
J Neurooncol. 2025 Jan;171(1):1-9. doi: 10.1007/s11060-024-04833-w. Epub 2024 Nov 28.
8
High level of aneuploidy and recurrent loss of chromosome 11 as relevant features of somatotroph pituitary tumors.高倍体和 11 号染色体的反复缺失是生长激素细胞垂体肿瘤的重要特征。
J Transl Med. 2024 Nov 4;22(1):994. doi: 10.1186/s12967-024-05736-0.
9
GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study.生长激素受体多态性指导预防肢端肥大症骨骼脆弱的二线治疗：一项初步研究的结果
Front Endocrinol (Lausanne). 2024 Aug 30;15:1414101. doi: 10.3389/fendo.2024.1414101. eCollection 2024.
10
Diagnosis and Management of Aggressive/Refractory Growth Hormone-Secreting Pituitary Neuroendocrine Tumors.侵袭性/难治性生长激素分泌型垂体神经内分泌肿瘤的诊断与管理
Int J Endocrinol. 2024 Aug 26;2024:5085905. doi: 10.1155/2024/5085905. eCollection 2024.
本文引用的文献
1
Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications.垂体腺瘤的遗传易感性：从发病机制到临床意义
Expert Rev Endocrinol Metab. 2011 Mar;6(2):195-214. doi: 10.1586/eem.10.87.
2
No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly.没有证据表明卡麦角林治疗肢端肥大症会对心脏瓣膜造成损害。
J Clin Endocrinol Metab. 2012 Sep;97(9):E1714-9. doi: 10.1210/jc.2012-1833. Epub 2012 Jun 21.
3
Clinical implications of growth hormone-secreting tumor subtypes.生长激素分泌肿瘤亚型的临床意义。
Endocrine. 2012 Aug;42(1):18-28. doi: 10.1007/s12020-012-9660-9. Epub 2012 Mar 21.
4
Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study.新诊断的肢端肥大症患者心脏病的决定因素：一项 10 年调查研究的结果。
Eur J Endocrinol. 2011 Nov;165(5):713-21. doi: 10.1530/EJE-11-0408. Epub 2011 Aug 25.
5
Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature.肢端肥大症患者的妊娠：来自两个转诊中心的经验和文献系统综述。
Clin Endocrinol (Oxf). 2012 Feb;76(2):264-71. doi: 10.1111/j.1365-2265.2011.04180.x.
6
Improvement of cardiac parameters in patients with acromegaly treated with medical therapies.医学治疗改善肢端肥大症患者的心脏参数。
Pituitary. 2012 Mar;15(1):50-8. doi: 10.1007/s11102-011-0318-z.
7
Influence of diabetes mellitus on vertebral fractures in men with acromegaly.糖尿病对肢端肥大症男性患者椎体骨折的影响。
Endocrine. 2011 Aug;40(1):102-8. doi: 10.1007/s12020-011-9486-x. Epub 2011 May 19.
8
High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly.长期控制良好的肢端肥大症患者，尽管骨密度正常，但仍存在高发的椎体骨折。
Eur J Endocrinol. 2011 Apr;164(4):475-83. doi: 10.1530/EJE-10-1005. Epub 2011 Jan 21.
9
Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy.奥曲肽长效释放剂（LAR）大剂量治疗对常规生长抑素类似物治疗控制不佳的肢端肥大症患者糖代谢的影响。
Eur J Endocrinol. 2011 Mar;164(3):341-7. doi: 10.1530/EJE-10-0811. Epub 2011 Jan 6.
10
Arthropathy in long-term cured acromegaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis.肢端肥大症长期治愈后的关节病的特征是骨赘形成而无关节间隙变窄：与全身性骨关节炎的比较。
Ann Rheum Dis. 2011 Feb;70(2):320-5. doi: 10.1136/ard.2010.131698. Epub 2010 Dec 3.
Zotero 插件